| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2019 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 205,000 | $131.41 | $26,938,687.68 | - | |
| Mar 25, 2019 | MRK Merck & Co., Inc. | Davis Robert M46 | EVP, Global Svcs &CFO | Sell | 192,572 | $82.38 | $15,863,118.50 | -58.3% | |
| Mar 22, 2019 | LLY Eli Lilly & Co | Zakrowski Donald A | Chief Accounting Officer | Sell | 1,000 | $128.50 | $128,500.00 | -17.9% | |
| Mar 20, 2019 | MRK Merck & Co., Inc. | Frazier Kenneth C | Chairman, President &CEO | Sell | 192,736 | $82.05 | $15,813,372.04 | -19.5% | |
| Mar 20, 2019 | ESPR Esperion Therapeutics, Inc. | Mayleben Timothy M | President &CEO | Buy | 5,000 | $43.48 | $217,400.00 | +9.8% | |
| Mar 19, 2019 | ESPR Esperion Therapeutics, Inc. | Vitullo Nicole | Director | Sell | 15,329 | $44.73 | $685,596.14 | -90.0% | |
| Mar 19, 2019 | ANIP Ani Pharmaceuticals Inc | Przybyl Arthur | President And CEO | Sell | 27,625 | $63.53 | $1,754,959.79 | -6.3% | |
| Mar 18, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Griffin Deborah A | Chief Accounting Officer | Sell | 943 | $16.63 | $15,677.47 | -100% | |
| Mar 18, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 356 | $16.63 | $5,918.54 | -1.0% | |
| Mar 18, 2019 | TEVA Teva Pharmaceutical Industries Ltd | O'Grady Brendan P. | EVP, North America Commercial | Sell | 1,179 | $16.63 | $19,600.99 | -45.9% | |
| Mar 18, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Stark David Matthew53 | Exec. VP Chief Legal Officer | Sell | 2,358 | $16.43 | $38,741.94 | -44.2% | |
| Mar 18, 2019 | TEVA Teva Pharmaceutical Industries Ltd | McClellan Michael James | EVP, Chief Financial Officer | Sell | 230 | $16.63 | $3,823.77 | -1.8% | |
| Mar 18, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Dethlefs Sven | EVP Global Marketing&Portfolio | Sell | 632 | $16.63 | $10,507.06 | -6.5% | |
| Mar 18, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Daniell Richard | Exec. VP, European Commercial | Sell | 1,297 | $16.64 | $21,588.05 | -100% | |
| Mar 18, 2019 | TEVA Teva Pharmaceutical Industries Ltd | Nazzi Gianfranco | EVP, Growth Markets Commercial | Sell | 320 | $16.64 | $5,326.27 | -3.4% | |
| Mar 18, 2019 | BUDZ Weed, Inc. | Breen Nicole M | Secretary And Treasurer | Sell | 51,500 | $1.16 | $59,820.00 | - | |
| Mar 15, 2019 | COLL Collegium Pharmaceutical, Inc | Heffernan Michael Thomas | Director | Sell | 25,000 | $17.17 | $429,250.00 | -9.9% | |
| Mar 15, 2019 | AMPH Amphastar Pharmaceuticals, Inc. | Shandell Jason B. | President And General Counsel | Sell | 32,336 | $20.35 | $657,930.49 | -9.2% | |
| Mar 15, 2019 | NVS Novartis AG | Novartis Bioventures Ltd | 10% Owner | Sell | 190,338 | $2.06 | $391,444.56 | -2.8% | |
| Mar 15, 2019 | CBDY Target Group Inc. | Schindermann Rubin | Ceo/ Director | Sell | 163,000 | $0.10 | $16,810.00 | -0.3% | |
| Mar 14, 2019 | TLRY Tilray Brands, Inc. | Castaneda Mark | CFO, Secretary, Treasurer | Sell | 30,000 | $70.43 | $2,112,816.00 | -78.5% | |
| Mar 14, 2019 | ALKS Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sell | 25,000 | $33.05 | $826,372.50 | -11.9% | |
| Mar 14, 2019 | ESPR Esperion Therapeutics, Inc. | Biotech Target N V55 | 10% Owner | Buy | 50,000 | $49.89 | $2,494,355.00 | +1.4% | |
| Mar 14, 2019 | ESPR Esperion Therapeutics, Inc. | Mayleben Timothy M | President &CEO | Buy | 5,000 | $48.73 | $243,650.00 | +10.8% | |
| Mar 14, 2019 | ALKS Alkermes Plc. | Wysenski Nancy | Director | Buy | 4,302 | $33.09 | $142,339.83 | +111.5% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.